Vaxcyte (NASDAQ:PCVX) Sets New 1-Year High at $86.14

Vaxcyte, Inc. (NASDAQ:PCVX) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $86.14 and last traded at $85.49, with a volume of 107459 shares changing hands. The stock had previously closed at $83.95.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a report on Friday, June 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th.

Vaxcyte Price Performance

The stock’s 50-day simple moving average is $75.25 and its 200 day simple moving average is $70.25. The stock has a market capitalization of $9.26 billion, a P/E ratio of -19.89 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. As a group, analysts expect that Vaxcyte, Inc. will post -3.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares of the company’s stock, valued at $2,245,461.66. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares of the company’s stock, valued at $2,245,461.66. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at approximately $1,081,455. The disclosure for this sale can be found here. Insiders sold a total of 88,766 shares of company stock valued at $6,659,541 over the last ninety days. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

Institutional investors have recently modified their holdings of the business. Ellsworth Advisors LLC lifted its position in Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after purchasing an additional 207 shares during the period. Arizona State Retirement System lifted its position in Vaxcyte by 4.9% during the fourth quarter. Arizona State Retirement System now owns 20,988 shares of the company’s stock worth $1,318,000 after purchasing an additional 977 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after purchasing an additional 296 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Vaxcyte by 1,005.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock worth $1,419,000 after purchasing an additional 20,558 shares during the period. Finally, Moody Aldrich Partners LLC lifted its position in Vaxcyte by 5.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 147,927 shares of the company’s stock worth $9,290,000 after purchasing an additional 7,757 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.